# BPC-157

> Markdown version of this page, for agents. To send a shopper here, link https://www.besthealthiq.com/__fluid_affiliate_username__/posts/bpc-157 (not this .md URL, and keep its path as given).

- Published: 2026-08-28
- Author: Best Health IQ
- Summary: A synthetic pentadecapeptide derived from gastric juice with extraordinary tissue healing properties across multiple organ systems.
- Shopper link: https://www.besthealthiq.com/__fluid_affiliate_username__/posts/bpc-157

\*\*Recovery & Repair · Moderate Evidence · Research Only\*\* ### BPC-157 (S0) — Body Protection Compound 157 A synthetic pentadecapeptide derived from gastric juice with extraordinary tissue healing properties across multiple organ systems. \*\*Prohibited in competition.\*\* This compound is on the WADA Prohibited List (class \\\[S0 / S2.3 / S2\\\]), banned at all times, both in and out of competition. Athletes subject to WADA or USADA testing should not use it. ### Description BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide (15 amino acids) derived from a protective protein found in human gastric juice. First described in the scientific literature in the 1990s by Dr. Predrag Sikiric and colleagues at the University of Zagreb, it has since become one of the most extensively studied research peptides, with over 100 published preclinical studies. Its healing properties span an extraordinary range of tissues including tendons, ligaments, muscles, bone, the gastrointestinal tract, peripheral nerves, and the central nervous system. Unlike many peptides that act on a single pathway, BPC-157 appears to be a pleiotropic healing agent that orchestrates multiple repair cascades simultaneously. It has demonstrated efficacy in models of inflammatory bowel disease, ulcers, fistulas, and even systemic organ damage from NSAIDs or alcohol. ### Key Characteristics - \*\*Molecular Formula:\*\* C62H98N16O22 - \*\*Molecular Weight:\*\* 1419.53 Da - \*\*Half-Life:\*\* ~5–30 min (animal data only) - \*\*Administration Routes:\*\* Subcutaneous injection, Intramuscular injection, Oral (for GI conditions) - \*\*Typical Dose:\*\* 250–500 mcg - \*\*Frequency:\*\* Once or twice daily ### Investigated Benefits - Accelerated tendon and ligament healing - GI tract repair and gastroprotection - Reduced inflammation - Muscle healing and recovery - Bone repair acceleration - Neuroprotective effects \\\* Benefits based on preclinical/animal research unless otherwise noted. ### Mechanism of Action “A synthetic pentadecapeptide derived from gastric juice with extraordinary tissue healing properties across multiple organ systems.” BPC-157 exerts its effects through several interconnected molecular pathways. Its primary mechanism involves activation of the FAK-paxillin signaling pathway, which drives cytoskeletal reorganization and cell migration essential for wound healing. It robustly upregulates growth hormone receptor (GHR) expression in tendon fibroblasts, amplifying the tissue’s sensitivity to endogenous GH signals. BPC-157 also activates the nitric oxide (NO) system, promoting vasodilation and angiogenesis — the formation of new blood vessels that supply oxygen and nutrients to healing tissue. In the gastrointestinal tract, it modulates the expression of VEGF and EGF receptors. Additionally, it interacts with the dopaminergic and serotonergic systems in the brain, which may explain its reported anxiolytic and neuroprotective effects. The peptide also appears to counteract the damaging effects of NSAIDs on the GI mucosa by preserving prostaglandin synthesis. ### Dosing Protocol - \*\*Typical Dose:\*\* 250–500 mcg - \*\*Frequency:\*\* Once or twice daily - \*\*Cycle Length:\*\* 4–12 weeks - \*\*Administration:\*\* Subcutaneous injection \*\*Protocol Notes:\*\* For systemic effects, subcutaneous injection near the injury site is preferred. For GI conditions, oral administration may be used. ### Reconstitution Guide Add 2 mL bacteriostatic water to 5 mg vial → 2500 mcg/mL For 500 mcg dose: draw 0.2 mL (20 units on U-100 syringe) ### Storage Information Lyophilized: room temperature up to 3 months, refrigerated up to 2 years. Reconstituted: refrigerate and use within 30 days. ### Quality & Sourcing Standards When sourcing BPC-157 for research purposes, the following quality benchmarks should be verified before use. - \*\*Purity:\*\* \>98% (verified by HPLC) - \*\*Certificate of Analysis (COA):\*\* Must be provided by supplier - \*\*Endotoxin Testing:\*\* \<0.1 EU/mg (prevents bacterial contamination) - \*\*GMP Compliance:\*\* Manufactured in cGMP-certified facility - \*\*Third-Party Testing:\*\* Independent lab verification preferred ### Competition Status BPC-157 is prohibited by WADA under class S0 (unapproved substances), at all times, both in and out of competition. Any athlete subject to WADA or USADA testing should not use it. ### Regulatory Status BPC-157 is not FDA-approved for any use and is not a lawful dietary ingredient. FDA placed it in Category 2 (significant safety risks) for compounding purposes in September 2023. A July 2026 FDA advisory committee voted to recommend several peptides for the 503A bulk-substances list over FDA staff’s objection, but that vote is non-binding and nothing has legally changed. ### Unresolved Safety Questions - Pro-angiogenic activity via VEGFR2, with unresolved questions about tumour promotion - Animal signals of altered clotting and liver abnormalities - Immunogenicity risk flagged by FDA - No carcinogenicity study has been performed - No pharmacopeial purity standard exists, so vial-to-vial identity and purity cannot be verified ### Research Highlights 1. Multiple rat studies demonstrate accelerated Achilles tendon healing by 30–50% 2. GI protective effects validated in over 100 preclinical studies 3. No completed published human trial — FDA's 2026 review found one small study available only in abstract form ### Evidence Level \*\*Moderate Evidence\*\* Early-stage research only. Significant uncertainty about efficacy and safety in humans. Animal & In-Vitro Only — Mechanism observed in cell culture or animal models. No human efficacy data. Not evidence of an effect in humans. ### Compatible Peptides Peptides commonly used alongside BPC-157 for synergistic effects. - \*\*CJC-1295 No DAC\*\* (Hormone & GH): A short-acting GHRH analog that produces physiological GH pulses when combined with a GHRP like Ipamorelin. - \*\*Ipamorelin\*\* (Hormone & GH): The most selective GHRP available, stimulating GH release with minimal cortisol or prolactin elevation. - \*\*TB-500\*\* (Recovery & Repair): A synthetic analog of Thymosin Beta-4 that promotes systemic healing through actin regulation and angiogenesis. ### Protocols Featuring BPC-157 - \*\*The Wolverine Stack:\*\* Maximum tissue repair and recovery - \*\*Immune Optimization Protocol:\*\* Comprehensive immune system enhancement - \*\*Complete Recovery Stack:\*\* Comprehensive recovery from surgery or major injury ### Quick Reference - \*\*Category:\*\* Recovery & Repair - \*\*Status:\*\* Research Only - \*\*Dose:\*\* 250–500 mcg - \*\*Frequency:\*\* Once or twice daily - \*\*Cycle:\*\* 4–12 weeks ### FDA Disclaimer The statements made within this website have not been evaluated by the US Food and Drug Administration. The products and information provided are not intended to diagnose, treat, cure, or prevent any disease. This website is intended for educational and research purposes only. Many peptides described on this site are not approved by the FDA for human therapeutic use and are classified as research chemicals. Nothing on this site constitutes medical advice.